The agreement will be extended through November 2023, and Regeneron will pay Decibel and extension fee of $10 million in the fourth quarter of 2022.

The collaboration was initially launched in 2017. Under the agreement, Decibel is developing three gene therapies that target congenital, monogenic hearing loss with Regeneron. In 2022, Decibel plans to begin a phase I/II clinical trial of DB-OTO, its lead gene therapy candidate, the two firms said.

Regeneron announces creative innovation 2021 winners
Regeneron announced the winners of its ninth annual Regeneron Prize for Creative Innovation, a competition designed to recognize creativity and independent...

Intellia, Regeneron highlight clinical results for CRISPR-Cas9 gene therapy
Intellia Therapeutics and Regeneron Pharmaceuticals have announced positive interim data from an ongoing phase I study of their in vivo candidate, NTLA-2001,...

Twist, Regeneron partner on genetics NGS panel
Twist Bioscience is collaborating with Regeneron subsidiary Regeneron Genetics Center to launch a custom next-generation sequencing (NGS) population genetics...

NIH recommends outpatient use of Regeneron's COVID-19 antibody cocktail
Regeneron Pharmaceuticals said the U.S. National Institutes of Health (NIH) strongly recommends its Regen-CoV as an outpatient treatment for COVID-19...

Regeneron publishes data supporting Ab cocktail as passive COVID-19 vaccine
Regeneron said that interim data from its ongoing phase III clinical trial supports the use of its Regen-CoV antibody (Ab) cocktail as a passive vaccine...